Crossmark

Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United States and Europe

Crossref DOI link: https://doi.org/10.1007/s11096-024-01824-9

Published Online: 2024-11-25

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sun, Yuyang

Xu, Kai

Yao, Hongting

Wei, Jingxuan

Ding, Baolong

Qian, Xiaodan

Su, Dan

Gong, Jinhong

Shang, Jingjing

Zhang, Lingli

Li, Xin https://orcid.org/0000-0003-3951-8061
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (Grant Number: 72074123, Grant Number: 72304150)
License Information

Text and Data Mining valid from 2024-11-25

Version of Record valid from 2024-11-25
More Information

Article History

Received: 7 September 2024

Accepted: 14 October 2024

First Online: 25 November 2024

Conflicts of interest

: The authors declare that they have no conflicts of interest.

Document is current

Any future updates will be listed below